A reportback from the Third National Conference on Women and HIV. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A reportback from the Third National Conference on Women and HIV.

Crit Path AIDS Proj. 1997 Summer;(No 32):25-7. Unique Identifier : AIDSLINE MED/97702726
Russell A; Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD; 20849-6003. 800-458-5231 ext. 5714. A fee will apply.; AIDS Coalition To Unleash Power Philadelphia, Philadelphia, PA.

Abstract: The Third National Conference on Women and HIV addressed a number of important issues related to infection rates, treatments, and research specific to women. While overall death rates for infected men decreased 15 percent in 1996, the rate for women increased 3 percent. The men's decrease is widely attributed to potent combination therapy, but women are penalized by persistent gaps in treatment. Antivirals were approved without sufficient data on how they act in women's bodies. Women are less likely than men to be prescribed protease inhibitors or have had viral load testing, and most drug trials either include small numbers of women or have no gender-specific tests. There has also been little research into the role of vaginal bacteria that appear to suppress HIV transmission.
Keywords: *HIV Infections/COMPLICATIONS *HIV Infections/DRUG THERAPY *HIV Infections/TRANSMISSION *Vagina/MICROBIOLOGY *Women's HealthKWDhivinfections/complicationsKWDhivinfections/drugtherapyKWDhivinfections/transmissionKWDvagina/microbiologyKWDwomen'shealth
971230
M97C1589

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .